<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620646</url>
  </required_header>
  <id_info>
    <org_study_id>2006-12-026</org_study_id>
    <nct_id>NCT00620646</nct_id>
  </id_info>
  <brief_title>The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol</brief_title>
  <acronym>4C-DES</acronym>
  <official_title>The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol in Clopidogrel Non-Responders After Drug-Eluting Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of increased dosing of clopidogrel and adding cilostazol to standard
      dose of clopidogrel after the insertion of drug-eluting stent in patients with clopidogrel
      resistance
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using dual antiplatelet agents with aspirin and clopidogrel is essential after drug-eluting
      stent implantation to prevent restenosis and stent thrombosis. However, variable platelet
      response and potential resistance to therapy have emerged with clopidogrel. Several studies
      showed that clopidogrel resistance is associated with increased cardiovascular events after
      coronary interventions. New antiplatelet therapeutic strategy of is needed in case of
      clopidogrel resistance. We started this study to compare the effect of double dosing of
      clopidogrel to 150mg per day and adding cilostazol to standard dose of clopidogrel after the
      insertion of drug-eluting stent in patients with clopidogrel resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% platelet inhibition with VeryfyNow-P2Y12 assay, platelet function test</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>P2Y12 reaction unit (PRU)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Clopidogrel Non-Responsiveness</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin plus increasing clopidogrel group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin, clopidogrel plus cilostazol group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin, clopidogrel</intervention_name>
    <description>aspirin 100 mg plus clopidogrel 150mg qd</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin, clopidogrel, cilostazol</intervention_name>
    <description>aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with clopidogrel resistance with treatment of dual antiplatelet agent, aspirin
             and clopidogrel, for more than 4 weeks after drug-eluting stent

          -  Clopidogrel resistance is defined as a patients with platelet inhibition less than 30%
             in platelet function test(VerifyNow-P2Y12 assayTM, Accumetrics, San Diego, CA, USA)

        Exclusion Criteria:

          -  Acute myocardial infarction within 2 weeks

          -  Unstable angina within 2 weeks

          -  History of using glycoprotein IIb/IIIa inhibitor within 1 month

          -  Cerebral infarction within 3 months

          -  Bleeding diathesis like coagulation disorder, thrombocytopenia (platelet count &lt;
             100,000/uL)

          -  history of gastrointestinal bleeding or genitourinary bleeding within 3 months

          -  needed oral anticoagulation

          -  aspirin, clopidogrel or cilostazol hypersensitivity

          -  congestive heart failure

          -  serum creatinine level &gt;2mg/dl

          -  malignancy

          -  using cytochrome P450 inhibitor (eg, itraconazole)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2008</study_first_submitted>
  <study_first_submitted_qc>February 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>February 11, 2009</last_update_submitted>
  <last_update_submitted_qc>February 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>HC Gwon</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>platelets</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

